Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Omega Therapeutics
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 23, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
April 09, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
March 28, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
March 06, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
December 04, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
November 13, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
November 07, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
October 31, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
October 16, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
October 11, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial
September 26, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
September 25, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
September 21, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Announces Updates to its Board of Directors
August 29, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 03, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Appoints Chris Schade to its Board of Directors
July 12, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
June 01, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting
May 31, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 04, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting
April 27, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma
March 30, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 01, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock
February 23, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 17, 2023
From
Omega Therapeutics
Via
GlobeNewswire
Tickers
OMGA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.